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Abstract
Schmallenberg virus (SBV) is an emerging orthobunyavirus of ruminants associated with outbreaks of congenital
malformations in aborted and stillborn animals. Since its discovery in November 2011, SBV has spread very rapidly to many
European countries. Here, we developed molecular and serological tools, and an experimental in vivo model as a platform to
study SBV pathogenesis, tropism and virus-host cell interactions. Using a synthetic biology approach, we developed a
reverse genetics system for the rapid rescue and genetic manipulation of SBV. We showed that SBV has a wide tropism in
cell culture and ‘‘synthetic’’ SBV replicates in vitro as efficiently as wild type virus. We developed an experimental mouse
model to study SBV infection and showed that this virus replicates abundantly in neurons where it causes cerebral malacia
and vacuolation of the cerebral cortex. These virus-induced acute lesions are useful in understanding the progression from
vacuolation to porencephaly and extensive tissue destruction, often observed in aborted lambs and calves in naturally
occurring Schmallenberg cases. Indeed, we detected high levels of SBV antigens in the neurons of the gray matter of brain
and spinal cord of naturally affected lambs and calves, suggesting that muscular hypoplasia observed in SBV-infected lambs
is mostly secondary to central nervous system damage. Finally, we investigated the molecular determinants of SBV
virulence. Interestingly, we found a biological SBV clone that after passage in cell culture displays increased virulence in
mice. We also found that a SBV deletion mutant of the non-structural NSs protein (SBVDNSs) is less virulent in mice than
wild type SBV. Attenuation of SBV virulence depends on the inability of SBVDNSs to block IFN synthesis in virus infected
cells. In conclusion, this work provides a useful experimental framework to study the biology and pathogenesis of SBV.
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Introduction
Approximately 30 percent of all infectious diseases that emerged
between 1990 and 2000 were caused by arthropod-borne viruses
(arbovirus) [1]. This is probably the result of a combination of
factors including a dramatic increase in travelling and commercial
exchanges, climate and ecological changes and increased livestock
production. In addition, changes in trading and commercial
policies have created optimal conditions for the movement of
infected vertebrate hosts and invertebrate vectors over wide
geographical areas.
Several European countries are currently experiencing the
emergence of a previously uncharacterized arbovirus of domesti-
cated ruminants, Schmallenberg virus (SBV) [2,3]. SBV infection
causes a mild disease in adult cattle characterized by reduced milk
production, pyrexia and diarrhea [4]. However, SBV infection of
susceptible pregnant animals can be associated with musculoskel-
etal and central nervous system malformations in stillborn or
newborn lambs and calves [3]. SBV was detected for the first time
in November 2011 in plasma samples collected from cows
displaying fever and diarrhea and farmed near the town of
Schmallenberg, Germany [3]. The first acute infections associated
with SBV were reported in August 2011, while the first
malformations in stillborn animals caused by this virus were
detected in The Netherlands in December 2011 [5]. Since then, 9
countries have reported congenital malformations and stillbirth
associated with the presence of SBV as of May 2012 [6]. In some
areas, SBV cross-reacting antibodies have been detected in as high
as to 100% of the cattle surveyed [7,8], although the clinical and
consequent economic impact of this infection is not completely
clear as yet [9].
Phylogenetic analysis revealed that SBV belongs to the genus
Orthobunyavirus within the Bunyaviridae, a large family comprising
hundreds of viruses able to infect a broad range of vertebrate and
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invertebrate hosts. Bunyaviruses are significant pathogens both in
humans and animals and cause a range of diseases including
febrile illnesses (Oropouche virus), encephalitis (La Crosse virus)
and hemorrhagic fevers (Rift Valley fever virus) [10].
SBV clusters with viruses from the Simbu serogroup, in
particular with viruses of the species Sathuperi virus including
Sathuperi virus (SATV), Douglas virus (DOUV) and Shamonda
virus (SHAV) currently classified within the Shamonda virus species
[11]. Viruses from Simbu serogroup have been associated with
abortions, stillbirths and malformations (arthrogryposis - hydran-
encephaly syndrome) in ruminants in Asia, Africa and Oceania.
Akabane virus (AKAV) is the most widely studied member of the
Simbu serogroup [12–17]. In the literature, there is relatively little
information on the diseases (if any) associated with SATV and
SHAV infection. Viruses from the Simbu serogroup have not been
detected in Europe before and given that SBV has not been found
in archived samples so far, it is likely that the first introduction of
SBV in Europe occurred in spring 2011. Given the current
available data, it is not possible to ascertain when and how SBV
was introduced in Europe.
With the exception of hantaviruses, all Bunyaviruses are
transmitted by arthropod vectors [10]. SBV is also thought to be
an arbovirus given its close relatedness to viruses of the Simbu
serogroup (all known to be transmitted by insects). In addition,
SBV has also been detected in pools of Culicoides biting midges in
Denmark [18].
Bunyaviruses are enveloped viruses and have a segmented single
stranded RNA genome of negative or ambisense polarity. The
viral genome comprises three RNA segments referred to as small
(S), medium (M) and large (L) which encode four structural
proteins: the nucleocapsid protein (N); two glycoproteins (Gn and
Gc); and the viral polymerase. Members of the Orthobunyavirus
encode two additional non-structural proteins, NSs and NSm. NSs
is encoded by an open reading frame in the S segment overlapping
the N gene while NSm is encoded by the M segment as a
polyprotein that is co-translationally cleaved into NSm, Gn and
Gc [10]. The NSs protein of Bunyamwera virus (BUNV), the
prototype of the family, is a non-essential gene product for viral
replication that has been shown to play a role in the inhibition of
the host cell mRNA and protein synthesis. The NSs protein
contributes to viral pathogenesis by blocking the production of
interferon (IFN) through transcriptional inhibition and conse-
quently inhibiting the innate responses of the host [19–21].
Studies on the molecular biology of RNA viruses has been
transformed by the development of reverse genetics that allow the
rescue of infectious virus from cloned cDNA copies of the viral
genomes [22]. A reverse genetics for BUNV has proven invaluable
in unraveling the underpinning mechanisms of viral replication
and pathogenesis of this virus family [19,21,23,24].
In this study, we developed reverse genetics platforms for SBV
and used them to characterize the biology and pathogenesis of this
emerging pathogen. We obtained SBV mutants revealing key
determinants of viral virulence and show that the viral non-
structural protein NSs counteracts the innate immunity of the host.
In addition, we show that SBV replicates in neurons of both
experimentally infected mice and in naturally occurring SBV
infected lambs and calves.
Results
In vitro tropism of SBV
Our first goal was to gain insight into the in vitro growth kinetics
of SBV in several cell lines derived from various animal species
and humans. SBV grew efficiently in all the cell lines tested
including sheep CPT-Tert, bovine BFAE, human 293T, dog
MDCK and hamster BHK-21 and BSR cells (Figure 1). SBV
reached titers of 106 PFU/ml at 48 h post-infection and induced
cytopathic effect (CPE) in most cell lines with the exception of
BFAE (data not shown). We found SBV to replicate very efficiently
in sheep CPT-Tert, where it induced well-defined plaques of
approximately 3 mm in diameter at 72 h post-infection. Conse-
quently, we used CPT-Tert for all the titrations of SBV performed
in this study.
Development of reverse genetics protocols for SBV
Several members of the Bunyaviridae have been successfully
rescued by reverse genetics [25–28]. The most successful and
simple approach involves the transfection of plasmids encoding
full-length antigenome viral RNAs under the control of the T7
polymerase promoter. We adopted a synthetic biology approach
and obtained the 3 plasmids harboring the full full-length
antigenome RNAs of each viral segment by in vitro synthesis,
using the sequences of the first SBV isolate available in the
International Nucleotide Sequence Database Collaboration in
January 2011 (accession numbers HE649912–HE649914) [3].
The complete sequences of the 59 and 39 untranslated regions
(UTRs) of the SBV S, M and L segments were unavailable at that
time and therefore we predicted the missing sequences based on
the high similarity with the sequences of AKAV. The rescue
plasmids were designed to contain the full-length antigenome
RNAs flanked by the T7 promoter immediately upstream of the 59
UTR and the hepatitis d ribozyme followed by T7 terminator
sequences immediately downstream of the 39 UTR as previously
described [29] within the pUC57 vector (Figure 2A). We
transfected the 3 antigenome-encoding plasmids in BSR-T7/5
cells, a BHK-derived cell line that constitutively expresses the T7
RNA polymerase [30]. Five days post transfection supernatants
were collected and the presence of virus was assessed by standard
plaque assays in CPT-Tert cells (Figure 2B). Negative controls
included cells transfected with only two of the rescue plasmids. We
successfully rescued SBV following this method, although in some
cases transfections did not result in viable rescued SBV.
From the in vitro growth assays described above, it appeared that
SBV infected 293T cells readily. Thus, we reasoned that it would
Author Summary
Schmallenberg virus (SBV) was discovered in Germany
(near the town of Schmallenberg) in November 2011 and
since then has been found to be the cause of malforma-
tions and stillbirths in ruminants. SBV has spread very
rapidly to many European countries including the Nether-
lands, Belgium, France and the United Kingdom. Very little
is known about the biological properties of this virus and
there is no vaccine available. In this study (i) we developed
an approach (called reverse genetics) that allows the
recovery of ‘‘synthetic’’ SBV under laboratory conditions;
(ii) we developed a mouse model of infection for SBV; (iii)
we showed that SBV replicates in neurons of experimen-
tally infected mice similar to naturally infected lambs and
calves; (iv) we developed viral mutants that are not as
pathogenic as the original virus due to the inability to
counteract the host cell defenses; and v) we identified
mutations that are associated with increased virulence.
This work provides the experimental tools to understand
how this newly emerged virus causes disease in ruminants.
In addition, it will now be possible to manipulate the SBV
genome in order to develop highly effective vaccines.
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be possible to rescue SBV more efficiently in this cell line known to
be highly transfectable if we provided the T7 RNA polymerase in
trans. To this end, we transfected 293T cells with the 3 SBV
antigenome plasmids (pUCSBVST7, pUCSBVMT7 and
pUCSBVLT7) along with a plasmid expressing the T7 RNA
polymerase under the control of the CMV immediate early
promoter (pCMV-T7) (Figure 2C). SBV was efficiently rescued
following this method, which we found overall more reproducible.
We were also able to rescue BUNV [31] in transiently transfected
293T cells (data not shown) demonstrating that this method can be
easily applied to other viruses within this family. sSBV rescued in
either 293T or BSR-T7/5 cells produced plaques of similar size
and shape to SBV (Figure 3A). In addition, we found that sSBV
grew with the same kinetics and reached approximately the same
titers of SBV in both sheep CPT-Tert and bovine BFAE cells
(Figure 3B). The presence of SBV in infected cells was confirmed
by western blotting of cell lysates of infected cells (Figure 3C).
These results indicate that wild type SBV and sSBV display similar
phenotypic characteristics in vitro.
Determination of the 39 and 59 UTR sequences of the SBV
genome segments
As mentioned above, we predicted the complete sequences of the 59
and 39 UTRs of the S, M and L segments of SBV on the basis of
published AKAV sequences.We performed 59 and 39RACEPCRs on
RNA extracted from SBV-infected cells in order to establish that the
sequence of sSBV faithfully represented the wild type field strain. The
sequences of the 39 and 59UTR of the M and L segments were 100%
identical to the predicted sequences used in the rescue plasmids for
sSBV (Figure 4). We did not find with our RACE PCR an extra 54
nucleotides that were reported in the 59 UTR of the M segment
(accession number HE649913) (not shown) which represent most likely
a sequencing artifact beyond the correct 39 end of the published
antigenome sequence. We found polymorphisms in SBV at positions
17 and 25 of the 39 UTR of the S segment. Some of the clones
analyzed contained thymine (T) at position 17 while others contained
an adenine (A) at that position. Similarly, at position 25, some clones
harbored a guanine (G) while other clones contained an A. The 39
UTR sequences of the synthesized plasmids used for reverse genetics
contained a T at position 17 and a G at position 25 indicating that the
original sequence prediction was correct (Figure 4). We also sequenced
the remaining full genome of the SBV strain used in this study and we
found it to be identical to the original sequences submitted in GenBank
(data not shown).
Characterization of SBV virulence in mice
We next investigated whether mice could be used as an
experimental model of SBV infection and pathogenesis. Firstly, we
inoculated 3 litters of 2-day old newborn NIH-Swiss mice (n = 8–
14) intracerebrally with 400 PFU of SBV, sSBV or cell culture
media as a control (study 1). All mice inoculated with SBV and
sSBV died within 8 days post-inoculation while all control mice
survived until the end of the experiment (Figure 5A, left panel).
These data clearly indicate that sSBV is as virulent as SBV at least
in this experimental model. In order to determine whether age
susceptibility existed for SBV infection in this mouse model, we
Figure 1. In vitro growth kinetics of SBV. A. Growth kinetics of SBV in a variety of established cell lines as indicated in the panel. Cells were
infected with SBV at a MOI of 0.05 and supernatants were collected at 4, 8, 24 and 48 h post-infection. Supernatants were then titrated in CPT-Tert
cells by limiting dilution analysis.
doi:10.1371/journal.ppat.1003133.g001
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inoculated litters of 10 and 18-day old NIH-Swiss mice as
described above with sSBV (study 2). We found that SBV infection
was lethal for most of the infected mice of these age groups,
displaying similar kinetics to the one displayed by SBV infection in
newborn mice (Figure 5A, right panel).
Histopathology of brains collected at 72 h post-infection revealed
bilateral symmetrical vacuolation and loosening of the neuropil of the
superficial cerebral cortex and the mesencephalon (Figure 5B–C). In
particular, we found small areas of haemorrhage within large areas of
malacia (necrosis of brain tissue) in the cerebral cortex (Figure 5C,
arrow). In brains collected at 120 h post-infection (Figure 5D–E) there
was randommultifocal vacuolation of the whitematter of the cerebrum
with small amount of nuclear debris (Figure 5E). There was a minimal,
multifocal perivascular infiltrate of lymphocytes in the adjacent grey
matter. The presence of SBVwas confirmed by immunohistochemistry
using a polyclonal antibody against the N protein. We found no
reactivity in mock-infectedmice (Figure 5F–G).We found patchy areas
of positive staining in brain sections taken from mice euthanized 48 h
post infection corresponding to the cytoplasm of neurons (Figure 5H–
I). Extensive immunoreactivity for SBVwas noted within the cerebrum
and mesencephalon of mice euthanized 72 h after inoculation
corresponding to infection of neurons. SBV antigens were also
detected in cells that morphologically resembled astrocytes (Fig. 5 J–K).
However, by immunofluorescence we were not able to detect SBV in
cells expressing GFAP (glial fibrillary acidic protein), a specific marker
for astrocytes (data not shown).
SBV is neurotropic in naturally in utero infected lambs
and calves
Next, we analysed tissue sections of brain and spinal cord from
a total of 8 naturally infected lambs and calves presenting
malformations commonly shown by animals congenitally infected
with SBV such as, arthrogryposis, brachygnatia inferior, torticol-
lis and curvature of the spine (Figure 6A) [32]. All samples
derived from abortion or stillborn cases that occurred in farms in
an SBV-endemic area in Germany, although we cannot ascertain
the time of infection nor the specific SBV strain involved in these
cases. Histopathology of brain sections showed lesions commonly
observed in SBV infected animals, including porencephaly
associated with widespread tissue destruction (Figure 6B). Clus-
ters of myelin laden macrophages (Fig. 6C, arrow) were noted in
areas of rarefaction. Glial nodules were randomly scattered
throughout the cerebrum (Fig. 6D, arrow) and there was a mild,
multifocal perivascular infiltrate of lymphocytes and macrophag-
es/microglia.
By immunohistochemistry, we detected SBV predominantly
in the cell body and processes of neurons of the grey matter,
similarly to what we have observed in mice (Figure 6E–F). In
addition, we found expression of abundant SBV antigen also in
the grey matter of the spinal cord (Figure 6I–J). Our controls
included serial sections of brains collected from SBV-infected
animals incubated with the pre-immune serum collected from
the rabbit used for the production of the polyclonal antibody
against SBV N protein (Figure 6G–H). No positive reaction
was observed in all the SBV positive or suspected cases that we
tested in this study. In addition, we used also as negative
controls tissue sections collected from the brains of lambs or
calves that died as result of unrelated pathologies from
Germany (collected before 2001) or Scotland (n = 7). As
expected, none of these negative controls showed immunore-
active cells (Figure 6K–L). Moreover, our studies strongly
indicate that SBV replicates in neurones of brain and spinal
cord of animal naturally infected with SBV.
Figure 2. Reverse genetics protocols for the rescue of SBV. A. Schematic representation of the antigenome plasmids used to rescue SBV. B
and C. Schematic representation of the strategies used for the rescue of SBV in BSR-T7/5 and 293T cells as described in the text. The two methods are
very similar with the exception that BSR-T7/5 stably express the T7 RNA polymerase and therefore these cells are transfected only with the SBV
antigenome plasmids. On the other hand 293T cells are transfected with the antigenome plasmids and an expression plasmid for the T7 RNA
polymerase.
doi:10.1371/journal.ppat.1003133.g002
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Molecular determinants of SBV virulence
The data obtained in calves and lambs suggested that newborn
NIH-Swiss mice inoculated intracerebrally can be an useful
experimental model of SBV infection. We attempted to further
exploit this tool in order to identify determinants of SBV virulence
using two different approaches. First, we attempted to attenuate
SBV in tissue culture by passaging the virus serially in CPT-Tert
cells, after which the resulting virus was plaque purified twice and
a stock generated in the same cells reaching a total of 32 passages
in tissue culture (virus referred to as SBVp32). In addition, given
that the NSs proteins of several Bunyaviruses including BUNV
[19], Rift Valley fever virus (RVFV) [33,34], AKAV [26] and La
Crosse virus (LCV) [35] have been shown to play key roles in viral
replication and pathogenesis, we attempted to rescue by reverse
genetics a SBV mutant lacking this non-structural protein.
Similarly to other orthobunyavirus, the predicted NSs of SBV is
encoded by the S segment in an overlapping reading frame within
the N gene. Because of the inherent capabilities of RNA viruses to
mutate and revert to a wild type phenotype, we introduced 2 silent
mutations in pUCSBVST7 within the N gene, abrogating the
second and third initiation codons of the NSs gene. Moreover, we
introduced 3 premature stop codons within NSs that did not affect
the N reading frame (Figure 7A). The resulting SBV NSs deletion
mutant (termed SBVDNSs) was then rescued in 293T cells as
described above. We confirmed the identity of the deleted NSs
mutant by sequencing.
We hypothesized that sequence changes were likely to have
occurred in SBVp32 following extensive passage and plaque
purification in tissue culture. Consequently, we amplified the
coding regions of all 3 SBV genome segments by RT-PCR and
sequenced the PCR products directly without cloning. We
identified a total of 17 nucleotide changes among the 3 genome
segments, most of which were non-synonymous mutations
(Figure 7C). Most of the mutations were identified within the M
and S segments. In particular, all the mutations found in the M
segment were located within Gc and NSm proteins and none
within Gn. We found that the S segment harbored the highest
number of mutations in relation to its size. Three of the 4 changes
found in the S segment of SBVp32 were non-synonymous
mutations of the N protein. In addition, 3 of these mutations
also affected the NSs protein leading to 1 synonymous and 2 non-
synonymous changes.
We next characterized the in vitro growth properties of the
rescued SBVDNSs and SBVp32 in sheep cells (Figure 7B). We
found that both SBVDNSs and SBVp32 had comparable growth
kinetics to sSBV and SBV respectively and both viruses reached
similar titers in infected cells.
Virulence of SBVDNSs and SBVp32 in experimentally
infected mice
Thereafter, we inoculated litters of 3 and 7-day old NIH-Swiss
mice intracerebrally with either 100 or 400 PFU of sSBV,
SBVDNSs, SBVp32 or cell culture media as a control (study 3).
All mice inoculated with sSBV died within 7 days post-inoculation,
with the exception of the litter of 7-day old mice inoculated with
100 PFU where 100% mortality was reached at day 9 post-
inoculation (Figure 8A). All control mice were healthy until the
end of the experiment. SBVDNSs showed an attenuated
phenotype. There was a clear delay in the time of death in the
groups inoculated with SBVDNSs and 40–60% of the inoculated
mice survived infection. Unexpectedly, SVBp32 was more virulent
than sSBV in this experimental model. Inoculation of SBVp32
resulted in 100% lethality by day 4 and 5 post-infection in 3 and 7-
day old mice respectively (Figure 8A). To gain insight into the
nature of the enhanced pathogenicity of SBVp32 observed in our
mouse model of infection, we inoculated litters of 7-day old NIH-
Swiss mice intracerebrally with SBVp32, sSBV (and media as a
control) and brain samples were collected at different time points
post-infection (study 4). Brain sections were analyzed by immu-
nohistochemistry to detect the presence of SBV. We detected the
presence of foci of virus-infected cells as early as 24 h post-
infection in samples derived from mice infected with SBVp32
(Figure 8B). In these mice, SBV antigens were widely spread by
48 h post-infection. In contrast, we first detected virus antigens at
72 h post-infection in brain sections derived from mice infected
with sSBV. These results suggest that SBVp32 is able to spread
faster than sSBV in the brain of experimentally infected mice.
The NSs protein of SBV counteracts the IFN response of
the host
The attenuation of virulence displayed by SBVDNSs suggested
that the NSs protein plays an important role in viral pathogenesis.
The NSs proteins of Orthobunyaviruses have been shown to
indirectly inhibit synthesis of IFN-a and b by shutting down
cellular mRNA synthesis [20,22,28,36]. Consequently, we per-
formed a series of assays to determine whether SBV and
SBVDNSs induce the synthesis of IFN in infected cells. Firstly,
we tested the human 2fTGH cells, which are known to be IFN
competent. Cell lines were infected with sSBV or SBVDNSs and at
Figure 3. In vitro phenotypic characterization of SBV and sSBV.
A. Comparison of plaques produced by wild type SBV and sSBV rescued
using BSR-T7/5 and 293T cells. B. Growth kinetics of SBV and sSBV. CPT-
Tert and BFAE cells were infected at a MOI of 0.05 for 90 min.
Supernatants were collected at the indicated times post-infection and
virus titer was measured using standard plaque assays in CPT-Tert cells.
C. The presence of SBV in CPT-Tert and BFAE cells infected with wild
type and rescued virus was confirmed by western blotting using
antibodies against the SBV N (nucleocapsid) protein.
doi:10.1371/journal.ppat.1003133.g003
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24 h post-infection the supernatant were collected and virus UV
inactivated. An IFN-protection assay was then performed in CPT-
Tert cells, which respond to IFN but are defective for its
production (data not shown) and thus are a good target cell line
for these experiments. Virus-inactivated supernatant from 2fTGH
cells was added to CPT-Tert cells and incubated for 24 h before
infection with encephalomyocarditis virus (EMCV), a virus
susceptible to IFN [37]. In parallel, cells were also incubated with
a known amount of universal IFN as a control. We found that
supernatants from cells infected with sSBV did not contain IFN as
they were not able to protect CPT-Tert cells from infection with
EMCV (Figure 9A). In contrast, supernatant from cells infected
with SBVDNSs was able to confer protection against infection of
the target cells by EMCV, and contained an average of 40 IFN
international units per ml (IU/ml).
Secondly, we investigated whether the lack of IFN production
upon infection with sSBV was due to the inhibition of
transcription of the type I IFN gene. To this end, we investigated
the presence of IFN-b mRNA by RT-PCR in 2fTGH cells
following infection with sSBV and SBVDNSs, or transfection with
poly I:C as a positive control. We did not detect IFN-b mRNA in
sSBV-infected or mock-infected cells, while it was clearly
detectable in cells infected with SBVDNSs or transfected with
poly I:C (Figure 9B). These results suggest that the SBV NSs
protein interferes with transcription of the IFN-b gene upon
infection.
Furthermore, in an attempt to evaluate the data obtained above
in a more relevant cell culture system, we repeated the IFN
protection assays in sheep primary endothelial cell cultures (ovEC)
and ovine trophoblast cells (oTr-1). Similarly to the data obtained
in human cells, we found that the supernatant from sSBV-infected
cells did not protect CPT-Tert cells from infection with EMCV.
On the other hand, supernatant from SBVDNSs-infected ovEC
and oTr-1 was found to contain abundant amounts of IFN
(estimated to be between 500 and 1000 IU/ml; Figure 9C).
Finally, to evaluate the role of SBV NSs protein in counteract-
ing the IFN response of the host in vivo, we inoculated litters of 7
day old IFN receptor null mice (IFNAR(2/2)) intracerebrally with
sSBV (n= 11), SBVDNSs (n = 10) and culture media as a control
(n = 8) (study 5). All the control mice survived during the
observation period (Figure 9D). All mice inoculated with
SBVDNSs died by 4 post-infection mice while 80% of mice
infected with sSBV died at the same time point and the remaining
20% died by day 6 post-infection. These data strongly suggest that
animals lacking a competent IFN response are equally susceptible
to sSBV and SBVDNSs, confirming the role of the NSs protein as
a modulator, at least indirectly, of the IFN response in vivo.
Discussion
SBV is a new emerging orthobunyavirus that has been
associated with abortions and malformations in sheep and cattle.
The Bunyaviridae include many viruses that have emerged or re-
emerged in the last decade such as OROPV, Henan fever virus,
Crimean-Congo hemorrhagic fever, RVFV, LCV and others [38–
42]. SBV was isolated for the first time in Germany in October
2011 [3]. However, the virus probably entered Northwestern
Europe in the border region of The Netherlands, Germany and
Belgium [8] and subsequently spread rapidly to neighboring
countries, including Luxembourg, France, Italy, Spain, Denmark
and the United Kingdom. In this study, we have established an
experimental platform that comprises both in vitro and in vivo
systems to study SBV biology and pathogenesis.
Studies on SBV have thus far been concentrated in under-
standing the animal species susceptible to this virus, the spreading
of the infection, and its impact on animal health and the farming
Figure 4. Sequences of 39 and 59 UTRs of SBV obtained by RACE PCR. A schematic representation of the genomes of the 3 viral segments is
shown. Sequences on the top of each segment (sSBV) indicate the sequence of the UTRs of the plasmids used for reverse genetics. The middle
sequences indicate the UTRs sequences inferred by RACE PCR (RACE1, RACE 2 etc). The bottom sequences indicate SBV UTRs reported in GenBank
(HE649914, HE649913 and HE649912). Positions highlighted in red correspond to nucleotides inferred for the construction of sSBV sequences based
on the AKAV sequence. Scores represent positions in the genome segments for which there was no sequence available in the submitted GenBank
sequences. Note that 54 nucleotides previously reported in the 59 UTR of the M segment that appeared to be a sequence artifact (i.e. not part of the
SBV genome) were not, as expected, detected by RACE and are not shown in the figure. Numbers shown in this figure take into account the corrected
39 and 59 UTRs.
doi:10.1371/journal.ppat.1003133.g004
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industry. In this study, we undertook several steps towards
understanding the molecular biology of SBV, its cellular tropism,
pathogenesis and host-virus interaction. Using a synthetic biology
approach, we developed two reverse genetics protocols for SBV, as
powerful tools to characterize this emerging pathogen and to
manipulate its genome. Using SBV sequences deposited in public
databases, we synthesized the three SBV antigenome segments in
vitro and rescued replication competent SBV in BSR-T7/5
transfected cells, as previously described for other bunyaviruses
[29]. We also developed an alternative rescue system, using the
plasmids above in transiently transfected 293T cells, where the T7
RNA polymerase was provided in trans. Using RACE RT-PCR
performed on viral RNA extracted from early passages of SBV
stocks we confirmed that the sequence identity of the viral UTRs
in our synthetic plasmids indeed corresponded to SBV. This
allowed us to provide for the first time the full-length sequence of
circulating SBV since previous reports only provided partial
sequences of the viral UTRs.
The ‘‘synthetic’’ SBV (sSBV) that we obtained was able to
replicate in vitro as efficiently as wild type SBV. In addition, both
wild type and sSBV were lethal in suckling mice injected
intracerebrally. This experimental mouse system proved to be
very useful in order to define SBV tropism. The histological lesions
within the brains of mice inoculated with SBV show a progression
from per-acute hemorrhage at 48 h post-infection to malacia at
72 h that extends to more widespread vacuolation of the white
matter at 96–120 h post-inoculation. The strong immunoreactivity
for SBV within the cerebral neurons of mice euthanized as early as
48 h post-inoculation, confirms that the histological changes
within the brain are related to SBV infection. Importantly, we
also found SBV to replicate in neurons of in utero infected calves
and lambs. In fetal sheep, SBV infection can result in cavitation of
the white matter of the cerebrum, cerebellar hypoplasia, mild
lymphohistiocytic perivascular encephalitis, and small glial nodules
scattered throughout the brain [32,43]. Thus, the cavitary lesions
observed in naturally SBV infected lambs/calves appear to be the
natural progression of vacuolar changes within the white matter
observed suckling mice acutely infected with SBV. The similarities
in the pathologic changes between naturally infected fetal sheep
and mice inoculated with SBV intracerebrally, suggest that the
mouse can be a useful model to study at least some aspects of SBV
virulence.
In this study we have made substantial progress by generating
an SBV antiserum that allowed us to define that neurons in the
brain seem to be the major target for viral replication in the
developing fetus. The limited time frame in which sheep fetuses
seem to be susceptible to SBV infection (28–50 days of gestation)
[44] coincides with the development of the blood brain barrier
(BBB). In sheep the BBB starts to develop between days 50 and 60
of gestation and reaches full development by day 123 [45]. Thus,
the virus could have easy access to the brain of the fetus during a
short period of time: from day 28 of gestation when the
placentomes (functional units of exchange between mother and
fetus in the ruminant placenta) develop until day 50 when the BBB
starts to develop. This would explain why disease in adult animals,
that have an intact BBB, is mild with no apparent development of
lesions in the CNS. Newborn mice have a fully mature BBB,
however the developing cerebral vessels can be fragile and allow
leakage of infectious agent [46]. SBV could potentially reach the
mouse brain tissue from subcutaneous inoculation proving an
Figure 5. Neuropathology of SBV infection in mice inocu-
lated intracerebrally. A. Left panel: survival plots of 2-day old
NIH-Swiss mice inoculated intracerebrally using the indicated
viruses or cell culture media as a control. Right panel: survival plots
of 10 and 18-day old NIH-Swiss mice inoculated as described in A.
B–E histopathology of brain sections from SBV-infected infected
mice stained with hematoxylin. B and C. brain sections from SBV-
infected mice at 72 h post-infection. Arrows indicate areas of
malacia and hemorrhage. D and E brain sections from SBV infected
mice at 120 h post-infection, showing areas of vacuolation in low
and high magnification respectively. F–K immunohistochemistry of
brain sections of mock-infected mice (F–G), or SBV infected mice at
48 h (H–I) or 72 h (J–K) post-infection using an SBV N antiserum as
described in Materials and Methods. Bars = 2 mm in B, F, H, J;
200 mm in C; 500 mm in D; 100 mm in E, G, I, K.
doi:10.1371/journal.ppat.1003133.g005
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opportunity to develop a challenge model of infection that would
better mimic natural exposure. It has been reported that
subcutaneous inoculation of IFNAR2/2 mice with SBV resulted
in weight loss and 10–20% mortality, therefore a different aspect
of SBV infection could be explored also with this model [47].
The malformations and deformities observed in SBV-infected
lambs and calves are accompanied by muscle hypoplasia and
demyelination. Here, we found SBV to infect the neurons of the
grey matter of the spinal cord, which would suggest that muscular
hypoplasia and muscular defects observed in SBV infected lambs
and calves are mostly secondary to damage of the central nervous
system (CNS).
Using reverse genetics we engineered a SBV NSs deletion
mutant as this protein has been found in other orthobunyaviruses
to be a virulence factor, acting by inhibiting cellular transcription
and therefore indirectly antagonizing the host IFN response.
SBVDNSs replicated at levels comparable to wild type SBV in
established cell lines, indicating that the NSs protein is not essential
for viral replication in vitro. However SBVDNSs was strongly
attenuated in newborn mice. It is unlikely that the attenuation
observed for SBVDNSs is due to a change in cell tropism. On the
contrary, we attribute its attenuated phenotype to its inability to
counteract the innate immune response of host. This is supported
by the fact that we were able to detect induction of IFN in IFN-
competent human cell lines and in sheep primary cells when they
were infected with SBVDNSs but not when they were infected
with wild type SBV. The production of IFN in SBVDNSs-infected
cells was associated with the presence of IFN-b transcripts, which
were not detected in cells infected with wild type SBV indicating
that the inhibition of IFN production occurred at the level of
transcription. Most importantly, we found no differences in the
virulence of sSBV and SBVDNSs in IFNAR(2/2) mice, further
reinforcing the notion that the SBV NSs protein is able to
modulate at least indirectly the host innate immune response.
Thus, the NSs protein of SBV acts as a virulence factor. Similar
roles have been identified for the NSs proteins of RVFV [36] and
LCV [35] underlying the importance of overcoming the host
innate immune response for efficient viral replication.
In an attempt to identify other determinants of SBV virulence,
we serially passaged SBV in CPT-Tert cells. Normally, serial
passage of pathogenic viruses in cell culture results in decreased
virulence especially when the cells used are defective in the
production of factors mediating innate immune responses.
However, using this approach, we unexpectedly obtained an
SBV mutant (SBVp32) with increased pathogenicity in suckling
mice. SBVp32 appeared to spread more rapidly than SBV in the
brain of infected animals. SBVp32 accumulated a variety of
mutations in all 3 viral segments. Of these, the ones found in the M
and S segment are potentially the most interesting ones given that:
i) we have already shown that the NSs is a virulence factor; and ii)
Figure 6. SBV tropism in the central nervous system of naturally in utero infected lambs and calves. A. Stillborn lamb showing signs of
congenital SBV infection including artrogryposis, brachygnatia inferior and torticollis. B–D: Tissue sections stained with hematoxylin and eosin
derived from brain of a lamb congenitally infected with SBV. Panel B illustrates cerebral cortex with porencephaly. The white matter is lacking as
indicated by (*). Adjacent grey matter is reduced in thickness (bar = 2 mm). C. Higher magnification micrographs showing areas of malacia and the
presence of myelin laden macrophages (arrow; bar = 20 mm). D. Glial nodule (arrow) and mild lymphohistiocytic perivascular infiltrate (bar = 50 mm).
E–L: Immunohistochemistry of tissue sections derived from brain (E–H) or spinal cord (I–J) of lambs congenitally infected with SBV. In sections shown
in panels E, F, I and J a SBV N polyclonal rabbit antiserum was used, while panels G–H show instead serial sections (of E and F) incubated with the pre-
immune serum. The use of SBV N antiserum reveals a strong positive reaction (characterized by the intracytoplasmic dark brown staining) in the cell
body and processes of neurons of the grey matter, while no staining was observed with serial sections incubated with the pre-immune serum. K–L:
Immunohistochemistry of control tissue sections derived from brains of sheep reared in Scotland and probed with the antiserum towards the SBV N
protein showed no immunoreactive cells.
doi:10.1371/journal.ppat.1003133.g006
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most of the mutations found in the M segment are present in the
Gc protein that is exposed in the outer surface of the virion and
thus is the principal target of neutralizing antibodies. The
mutations generated in Gc in an immunological unconstrained
environment could be associated for example with an increased
cell receptor affinity.
In conclusion, our synthetic biology approach demonstrates
that, at least for the Bunyaviridae, it is possible very rapidly to
investigate and characterize an emerging virus whilst only having
knowledge of the complete sequence of the virus. Using synthetic
plasmids we developed 2 reverse genetic protocols for the rescue of
replication competent SBV. Most importantly, we developed a
mouse model of infection that allowed us to identify a viral gene
critical for virulence. Viral tropism for neurons of the CNS was
shown to be similar in experimentally infected mice and naturally
infected calves and lambs. Altogether, the molecular virology tools
that we generated and the findings of this work open new avenues




All experimental procedures carried out in this study were approved
by the ethical committee of the Istituto G. Caporale (protocol number
5383/2012) and further approved by the Italian Ministry of Health
(Ministero della Salute) in accordance with Council Directive 86/609/
EEC of the European Union and the Italian D.Igs 116/92.
Cell lines
The 293T, 2fTGH, BHK-21, BSR and MDCK cell lines were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). BSR-T7/5 (provided
by Karl Conzelmann) cells stably expressing the T7 polymerase
were grown in Glasgow modified Eagle’s medium supplemented
with 10% FBS, 10% of tryptose phosphate broth and G418 at a
final concentration of 1 mg/ml. Sheep choroid plexus cells (CPT-
Tert) were grown in Iscove’s modified Dulbecco’s medium
supplemented with 10% FBS (provided by David Griffiths) [48].
Bovine fetal aorta endothelial cells (BFAE, Health Protection
Agency collection number 87022601) were cultured in Ham’s F12
medium supplemented with 20% FBS. Ovine trophoblast cells,
oTr-1, (provided by Thomas Spencer) [49] were cultured in
DMEM/F12 media supplemented with 15% FBS, 1 mM pyru-
vate, 700 nM of human recombinant insulin and 0.1 mM of
nonessential amino acids. All cell lines were cultured at 37uC in a
5% CO2 and 95% humidified atmosphere and were supplemented
with 10,000 U/ml of penicillin and 10 mg/ml of streptomycin.
Primary endothelial cell cultures
Ovine aortic endothelial (ovEC) cells were isolated by collage-
nase treatment using a method adapted from Gillespie et al. [50].
Aortas were harvested from recently euthanized animals and
washed twice in sterile PBS. The aortas were then incubated at
room temperature for 1 h in DMEM supplemented with 5% FBS,
25 mg/ml penicillin/streptomycin and 50 ng/ml amphotericin B.
After incubation, the aortas were placed into collagenase in a Petri
Figure 7. In vitro phenotypic characteristics of SBVDNSs and SBVp32. A. Strategy used to generate SBVSDNSs. Nucleotide (antigenome) and
amino acid sequences showing the translation start site of the NSs in an overlapping reading frame within the N gene are indicated (top sequences).
Bottom sequences indicate silent mutations (low case) introduced in N that abrogate expression of the NSs protein. B. Growth kinetics of SBV lacking
the NSs protein and SBVp32. CPT-Tert cells were infected at a MOI of 0.05 for 90 min. Supernatants were collected at the indicated times post-
infection and the virus titer was measured using standard plaque assays in CPT-Tert cells. C. Schematic representation showing the nucleotide
differences (red dots) found in SBVp32 in relation to SBV. Only the coding regions of the antigenomes of the 4 known genes are shown. Non-
synonymous mutations are indicated with an asterisk.
doi:10.1371/journal.ppat.1003133.g007
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dish (2 mg/ml in DMEM) for 1 h at 37uC. After incubation, the
endothelial cells were removed by scraping and seeded in 6-well
plates. Cells were maintained at 37uC and 5% CO2 in large vessel
endothelial cell basal medium (TCS cellworks) supplemented with
20% FBS, human large vessel endothelial cell growth supplement
(TCS cellworks), 25 mg/ml penicillin/streptomycin and 50 ng/ml
amphotericin B. Cells were confirmed as endothelial cells by
assessing their morphology using light microscopy and by
immunofluorescence using antibodies against endothelial and
smooth muscle cell markers. Cells used for this study were only
passaged once.
Antibodies
Antisera used in this study included a rabbit polyclonal
antiserum against the SBV N protein expressed in bacteria as
Glutathione-S-transferase (GST)-tagged recombinant protein
(Proteintech). Antibodies against CD-31 (marker for endothelial
cells) and actin (smooth muscle marker) were purchased from
Source Bioscience and Abcam respectively.
Viruses
Wild type SBV was originally isolated at the Friedrich-Loeffler-
Institut (Germany). This virus was initially isolated from the blood
of an infected cow and passaged once in KC cells and 6 times in
BHK-21 cells. The virus was plaque purified and stocks were
produced in BHK-21 cells. Virus titers were determined by
standard plaque assays in CPT-Tert cells and expressed as plaque
forming units per milliliter (PFU/ml). Encephalomyocarditis virus
was provided by Rick Randall [37].
Plasmids
pUCSBVST7, pUCSBVMT7 and pUCSBVLT7 encode the
full-length antigenomic S, M and L SBV segments and were used
for the SBV reverse genetics protocols described in this study (see
below). In each plasmid, the SBV antigenome is placed
downstream of the bacteriophage T7 promoter and upstream of
the hepatitis d ribozyme and the T7 terminator similarly to what
described previously for other Bunyaviruses [29]. Sequences of
pUCSBVST7, pUCSBVMT7 and pUCSBVLT7 were synthe-
sized commercially and were derived from the incomplete SBV
sequences available in GenBank in January 2012 (HE649912;
HE649913; and HE649914). Where missing, the 59 and 39 end
sequences for each genome segment (not available in GenBank at
that time) were predicted by alignment of AKAV 59 and 39
sequences. pUCSBVDNSsT7 was obtained by inserting 5 point
mutations in pUCSBVST7 as described below. Two mutations
Figure 8. Virulence of SBV mutants in suckling NIH-Swiss mice. A. 3 and 7-day old mice were inoculated intracerebrally with either 100 or
400 PFU with the indicated viruses or cell culture media as a control. Survival plots show that SBVDNSs possesses an attenuated phenotype while
SBVp32 is more virulent than sSBV. B. Immunohistochemistry of brain sections derived from NIH-Swiss mice inoculated with sSBV or SBVp32 and
killed at various time points post-infection as indicated in the figure. Immunohistochemistry was performed using an SBV N antiserum as described in
Materials and Methods. At the early time points SBV antigens are detected only in sections derived from SBVp32 infected mice (Bar = 500 mm).
doi:10.1371/journal.ppat.1003133.g008
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altered the second and third initiation codons in the NSs while the
remaining 3 introduced premature stop codons. pCMV-T7
expresses the T7 polymerase under the control of the CMV
immediate early promoter.
Reverse genetics
293T cells or BSR-T7/5 cells were plated in 6 well plates
one day before transfection without in a final volume of 2 ml of
tissue culture media without antibiotics. For rescue in BSR-
T7/5 cells, 1 mg of each antigenome-encoding plasmid was
transfected using Fugene HD at a 1:3 ratio (mg of plasmid: ml of
Fugene). For rescue in 293T cells, a plasmid expressing the T7
polymerase under the control of the CMV promoter was
transfected alongside the plasmids containing the SBV
antigenomes (or derived deletion mutant antigenomes). In
both protocols, cells transfected with only two genomic
segments were used as negative control. Supernatants were
collected 5 days post transfection, clarified by low speed
centrifugation and the presence of virus (termed sSBV for
‘‘synthetic SBV’’ in this study) was assessed by standard plaque
assays in CPT-Tert cells as already described [51]. Virus stocks
were generated from plaque purified virus in CPT-Tert cells.
Virus growth curves
The in vitro growth kinetics of SBV was determined by infecting
a variety of cell lines at a multiplicity of infection (MOI) of 0.05.
The presence of infectious virus was then assessed from clarified
supernatants collected at different time points post infection by end
point dilution analysis performed in CPT-Tert cells. Each
experiment was performed in triplicate and repeated at least twice.
RACE analysis
The 59 and 39 ends of the 3 genome segments of SBV were
sequenced using the 59/39 RACE kit according to the manufac-
turer’s instructions (Roche). 59 RACE was carried out on the
genome strand to obtain the sequence of the 59 end of the virus
segments. Briefly, 1 mg total RNA extracted from SBV infected
BHK-21 cells was reverse transcribed using a gene specific cDNA
synthesis primer. The synthesised cDNA was column purified and
poly-A tailed at the 39 end and then amplified using the oligodT
anchor primer and a second nested gene specific primer. To
obtain the 39 end of the virus segments, 39 RACE was performed
on the genome strand. Briefly, 1 mg total RNA extracted from
SBV infected BHK-21 cells was poly-A tailed at the 39 end of the
RNA using poly A polymerase (NEB) according to the manufac-
Figure 9. SBVSDNSs induces the production of IFN. A. IFN protection assay. 2fGTH cells were infected with the indicated viruses and
supernatants were collected 24 h post infection. Supernatants were UV treated to remove infectious virus and fed to CPT-Tert cells after serial
dilution. CPT-Tert cells were later infected with EMCV and the presence of CPE monitored and compared to cells supplemented with known amounts
of universal IFN. B. The induction of IFN-b mRNA was investigated by RT-PCR from RNA extracted from 2fGTH cells infected with virus as indicated or
transfected with Poly I:C as a positive control. To control for the presence of residual genomic DNA all the samples were amplified after reverse
transcription performed without reverse transcriptase (top panel, indicated as+/2RT). The quality of the extracted RNA was verified by the
amplification of the 45S ribosomal RNA (middle panel). The presence of virus was confirmed by the amplification of part of the SBV S segment
(bottom panel). C. IFN protection assay performed in primary ovine trophoblast cell (oTr-1) and primary ovine endothelial cells as described in A. D.
Survival plots of 7 day old IFNAR(2/2) mice inoculated intracerebrally with sSBV, SBVSDNSs or cell culture media as a control. Data indicate that
SBVDNSs is as virulent as sSBV in these mice that lack an intact IFN system.
doi:10.1371/journal.ppat.1003133.g009
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turer’s protocol. The poly-A tailed RNA was reversed transcribed
using the oligodT anchor primer. cDNA was then amplified using
the anchor primer and a nested gene specific primer. Primer
sequences are available upon request.
Interferon detection
2fTGH cells were plated at a density of 1.76105 cells/ml in 24
well plates. Cells were infected with the indicated viruses at MOI
of 5 or transfected with poly I:C (10 ng) using Lipofectamine 2000
according to the manufacturer’s protocol. Cells were incubated at
37uC for 24 h, then lysed in TRizol Reagent (Invitrogen) and
RNA extracted according to the manufacturer’s protocol. 1 mg of
total RNA was reverse transcribed using Superscript III (Invitro-
gen) according to the manufacturer’s instructions. This cDNA was
used as a template for amplification of the SBV S segment or 45S
RNA using GoTaq polymerase (Promega) following the manu-
facturer’s protocol. The sequences of the primers used for SBV
detection are available on request. Primers for the amplification of
the IFN-b and 45S RNAs have been previously published [52,53].
Interferon protection assays
Measurement of IFN levels was based on the methods described
previously [37,54]. 2fTGH, OvEC and oTr-1 cells were first
seeded in 12-well plates and incubated for 2 days. Cells were then
infected with the appropriate virus at a MOI of 5, 4 and 2
respectively and the medium was collected 24 h later. The
medium was UV-treated for 5 minutes using a Spectrolinker XL-
1500 UV crosslinker (Spectronics Corporation) in order to remove
any infectious virus. CPT-Tert cells were then seeded in 96-well
plates and 24 h later 2-fold serial dilutions (in duplicate) of the
UV-treated media were added. Cells were then further incubated
for 24 h. In parallel, cells were also incubated with 2-fold dilutions
of a known amount of universal IFN. Cells were then infected with
encephalomyocarditis virus (EMCV) and incubated for an
additional 48 h. The levels of IFN were calculated by monitoring
wells that were protected from cell death induced by EMCV and
comparing them to the universal IFN control.
Western blotting
SDS-PAGE and Western blots were performed from total cell
lysates prepared 24 h post-infection as previously described
[55,56]. SBV was detected using a rabbit polyclonal antibody
against the SBV nucleocapsid protein.
In vivo pathogenicity studies
Animal experiments were carried out at the Istituto G. Caporale
(Teramo, Italy) following local and national approved protocols for
animal experimentation. Study 1. Litters of 2-day old NIH-Swiss
mice were inoculated intra-cerebrally with 400 PFU of SBV, sSBV
or mock inoculated using cell culture medium. Animals were
monitored daily for signs of disease for a period of 14 days.
Study 2. Litters of 10-day and 18-day old NIH-Swiss mice
were inoculated intracerebrally with 400 PFU of sSBV and
monitored for signs of disease as above.
Study 3. Litters of 3 and 7-day old mice were inoculated
intracerebrally with 100 or 400 PFU with sSBV, SBVp32,
SBVDNSs or cell culture media and monitored for signs of disease
for a period of 14 days.
Study 4. Litters of 7-day old NIH-Swiss mice were inoculated
intracerebrally with 400 PFU with sSBV, SBVp32, or cell culture
media and 2 animals per group were euthanized at 24, 48, 72 and
96 h post-infection.
Study 5. Litters of 4 day old mice deficient of the type I IFN
receptor (IFN Alpha Ro/o IFN(2/2) 129/Sv) were inoculated
intracerebrally with 400 PFU with sSBV, SBVDNSs, or cell
culture media as a control and monitored for signs of disease.
Histopathology and immunohistochemistry
Brains from infected and control mice were collected and fixed
in 10% neutral buffered formalin and paraffin embedded
following standard histological procedures. In addition, brain
tissues were also collected from 6 lambs and 5 calves born in North
Rhine-Westphalia, a SBV-endemic area of Germany. At post-
mortem, animals presented a variety of malformations including
arthrogryposis, brachygnatia, torticollis, cerebellar hypoplasia,
hydrocephalus, muscular hypoplasia. Negative controls included
brain sections derived from a sheep and 3 calves, which died as a
result of diseases unrelated to SBV-infection in Germany between
1994 and 2001. We also used as negative controls 3 brain tissues
from Scotland, an area so far free of SBV infection. Tissue sections
(4–6 mm) from mice, lambs and calves were stained with
hematoxylin and eosin for histopathological examination. Sections
were also examined for the presence of the SBV N protein using a
specific antiserum and the EnVision (DAKO) detection system as
described before [51,57].
Accession numbers
The sequences of the synthetic SBV genomic segments have
been deposited in GenBank (accession numbers JX853179,
JX853180, JX853181).
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